fe1628d5-92d9-4e5c-a441-531b699014f1
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 65
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.660
- INTERFERON_GAMMA_RESPONSE+0.590
- ALLOGRAFT_REJECTION+0.520
- IL6_JAK_STAT3_SIGNALING+0.400
- INFLAMMATORY_RESPONSE+0.370
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.340
- PANCREAS_BETA_CELLS+0.320
- OXIDATIVE_PHOSPHORYLATION+0.310
- COMPLEMENT+0.260
- IL2_STAT5_SIGNALING+0.260
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.320
- TGF_BETA_SIGNALING-0.300
- CHOLESTEROL_HOMEOSTASIS-0.230
- PROTEIN_SECRETION-0.230
- UV_RESPONSE_DN-0.210
- MYOGENESIS-0.190
- ANGIOGENESIS-0.180
- COAGULATION-0.180
- KRAS_SIGNALING_DN-0.180
- APICAL_JUNCTION-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-EW-A1PB-01A-11R-A144-07 | — | E | 0.871 |
| 2 | 7c8246a6-3f2c-42e1-b09f-959cfbf7fd5a | — | — | 0.812 |
| 3 | TCGA-E9-A22D-01A-11R-A157-07 | — | D | 0.804 |
| 4 | 20080305.TNBC | — | D | 0.803 |
| 5 | TCGA-T2-A6WX-01A-12R-A34R-07 | — | — | 0.790 |
| 6 | DRR168511 | — | — | 0.781 |
| 7 | GSM5359439 | — | — | 0.777 |
| 8 | SRR35579807 | — | C | 0.767 |
| 9 | TCGA-AR-A0U0-01A-11R-A109-07 | — | E | 0.767 |
| 10 | TCGA-UF-A7JO-01A-11R-A34R-07 | — | — | 0.767 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.660 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.590 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.520 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.340 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.320 | Cobimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.310 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.260 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.260 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.250 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.220 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.210 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.210 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| HYPOXIA | 0.160 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.150 | Inavolisib | — uncovered |
| APOPTOSIS | 0.140 | Idelalisib | — uncovered |